GYNECOLOGIC CANCERS

Thomas J. Herzog, MD, provided an overview of clinical research in cervical, endometrial, and ovarian cancer settings that covered cancer vaccines, adoptive T-cell transfer therapy, and immune checkpoint inhibitors during the 14th Annual New Orleans Summer Cancer Meeting.

The FDA has granted an accelerated approval to the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced endometrial cancer who have disease progression following prior systemic therapy. The indication applies to patients who are not candidates for curative surgery or radiation and who have disease that is not microsatellite instability–high or mismatch repair deficient.

To improve the efficacy of chimeric antigen receptor T-cell therapies, Nirali N. Shah, MD, MHSc, suggested including new constructs that target more than 1 antigen in patients with acute lymphoblastic leukemia, during a presentation at the 2019 SOHO Annual Meeting.<br /> &nbsp;

Avelumab demonstrated promising efficacy in treating patients with mismatch repair&ndash;deficient endometrial cancer, according to the results of a phase II study published in the&nbsp;Journal of Clinical Oncology.&nbsp;

Sarah Ferguson, MD, FRCSC, discusses her experience being involved in a population-based study of women with cervical cancer treated with a radical hysterectomy.

In an interview with&nbsp;Targeted Oncology, Amir A.&nbsp;Jazaeri, MD,&nbsp;discussed the role of LN-145 in cervical cancer. He also highlighted next steps for this treatment approach and the promise of TIL therapy in cervical cancer, as well as other tumor types.

John L. Marshall, MD, spoke with a group of physicians during a&nbsp;Targeted Oncology&nbsp;live case-based peer perspectives discussion on the different classes of agents available to treat patients with gastrointestinal cancers.

Heather Williams, MD provided background on the study of nivolumab as salvage therapy in heavily pretreated patients with gynecologic malignancies in an interview with <em>Targeted Oncology</em>.<strong> </strong>

Krishnansu S. Tewari, MD, discussed the results from the phase III clinical trial investigating the addition of bevacizumab to standard chemotherapy treatment following surgery in patients with advanced ovarian cancer, and the next steps for research regarding the role of bevacizumab in ovarian cancer treatment.

Richard T. Penson, MD, discusses the toxicities that were demonstrated in the long-term follow-up of the phase III SOLO3 trial. This multicenter, open-label trial investigated single-agent olaparib in patients with platinum-sensitive, relapsed, BRCA-mutated ovarian cancer who have received at least 2 prior lines of chemotherapy.

Management of neuroendocrine liver metastases relies on many treatment modalities, ranging from surgery to ablation. Clinicians have in their armamentarium interventional radiology techniques that use regional and systemic treatments spanning a diverse group of biologic, cytotoxic, and targeted agents.

Howard S. Hochster, MD, discusses the role of TAS-102 in patients with gastric/gastroesophageal junction or colorectal cancer in comparison to fluorouracil.

Olaparib in combination with bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival as a frontline maintenance regimen compared with bevacizumab alone in women with advanced ovarian cancer, according to early results from the phase III PAOLA-1 trial.

Ovarian Cancer

Heavily Pretreated Recurrent Ovarian Cancer

Laura Dawson, MD, FRCPC, FASTRO, has been selected as the president-elect of the American Society for Radiation Oncology and will begin her term at the society&rsquo;s 61st Annual Meeting, which is being held in Chicago, Illinois on September 15-18.

Ana Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d&rsquo;Hebron University Hospital,&nbsp;and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing anti&ndash;PD-1 monotherapy with&nbsp;dostarlimab in patients with microsatellite instability&ndash;high and microsatellite stable endometrial cancer.&nbsp;

In the phase III PRIMA trial, niraparib demonstrated a benefit in progression-free survival compared with placebo when used as maintenance therapy following platinum-based chemotherapy for patients with ovarian cancer treated in the first line.&nbsp;The PFS benefit was found to be statistically significant, regardless of patients&rsquo; biomarker status, meeting the primary endpoint of the trial.&nbsp;